Press & News

People are different and so is their cancer, patients should be treated individually.

New The power of precision, For Every Oncologist, Today

With IndiTreat, 2cureX makes the testing of chemotherapeutic agents on patient-derived microtumors an operational reality.

Latest News

Dr. Raphael Gruber joins 2cureX as new Medical Director

Latest press and news

May 9

IR

2cureX presents IndiTreat® clinical results at the Society for Functional Precision Medicine

May 6

IR

Regulatory

Swedish

2cureX utser Sedermera Corporate Finance AB till likviditetsgarant för bolagets aktie

May 6

IR

Regulatory

2cureX appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company´s share

May 5

IR

Redeye research interview with 2cureX CEO, Fernando Andreu

May 3

IR

Regulatory

Report

2cureX publishes the annual report for the fiscal year 2021

May 3

IR

Regulatory

Report

Swedish

2cureX offentliggör årsredovisning för räkenskapsåret 2021

Apr 29

IR

Regulatory

Swedish

Rättelse: Korrektion till “Kallelse till årsstämma i 2cureX AB” utfärdad den 21 april 2022

Apr 22

IR

Regulatory

Correction of “Notice of annual general meeting of 2cureX AB (publ)” issued on 21st April 2022